Oncology
Plant compounds and gut microbiota activity influence how cancer drugs work and should be considered in treatment.
Nanoparticle-based approaches are a promising strategy for treating colorectal cancer.
Genetic factors can influence tumor-associated microbes, offering insights into colorectal cancer progression and potential therapeutic targets.
Certain bile acids produced by gut microbes can interact with specific receptors in the body, influencing immune cells to fight tumors.
Each Fusobacterium nucleatum population has unique traits and distribution patterns across body sites and conditions such as colorectal cancer and Crohn’s disease.
The microbiota plays a protective role against colorectal cancer by regulating Snhg9.
Probiotics such as Lactobacillus can complement breast cancer therapy to improve prevention and treatment.
The presence of specific microbes in the gut microbiota can serve as biomarkers for predicting the efficacy of immunotherapy.
Specific gut microbiota features correlate with better responses to immunotherapy in people with melanoma.
The study revealed that MS-20 dramatically improved treatment outcomes, tripling the objective response rate (ORR) to 75% when combined with Keytruda.
